Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, July 03, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) immunotherapies designed

GlobeNewswire01:05

Cantor Fitzgerald Reiterates Overweight on Cidara Therapeutics

Cantor Fitzgerald analyst Louise Chen reiterates Cidara Therapeutics (NASDAQ:CDTX) with a Overweight.

BenzingaJun 21 01:30

Cidara Therapeutics(CDTX.US) Officer Buys US$105.68K in Common Stock

$Cidara Therapeutics(CDTX.US)$ Officer Stein Jeffrey purchased 8,000 shares of common stock on Jun 7, 2024 at an average price of $13.21 for a total value of $105.68K.Source: Announcement What is stat

Futu NewsJun 12 07:07

Cidara Therapeutics to Present Preclinical Data on CD388 at ASM Microbe 2024 Conference

SAN DIEGO, May 30, 2024 — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) immunotherapies designed to

Cidara TherapeuticsMay 30 12:00

Cidara Therapeutics Inc. Hits Snag: Delayed 10-K Filing Complicates Capital Raising Efforts

TipRanksMay 17 14:01

Needham Reiterates Buy on Cidara Therapeutics, Maintains $25 Price Target

Needham analyst Joseph Stringer reiterates Cidara Therapeutics (NASDAQ:CDTX) with a Buy and maintains $25 price target.

BenzingaMay 16 19:05